CHONQUER: A phase 3, multicentre, double blind, randomised, placebo-controlled study of ivosidenib in participants ≥ 18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
EORTC QOL: Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients
FaR-RMS: An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma
ICONIC: Improving outcomes through collaboration in osteosarcoma
Inter-Ewings: International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma - Trial 1 (INTER-EWING-1)
KINDRED ASSG: The International Sarcoma Kindred study: A global multi-site prospective cancer genetics study
MIGHTY - CGCATF-2021/100014: MultI-modular Chimeric Antigen Receptor T cells tarGeting B7-H3 in Children, Teenage & Young adult sarcoma (rhabdomyosarcoma, Ewing sarcoma or desmoplastic small round cell tumour)
NIR-DT- 401: SpringWorks: A single-arm, open-label phase IV study of Nirogacestat in adult premenopausal females with Desmoid Tumors/Aggressive Fibromatosis(DT/AF)
PH1 Inhibrix: An open-label, multicentre, first-in-human, phase 1 dose escalation and multicohort expansion study of INBRX-109 in subjects with locally advanced or metastatic solid tumours, including sarcomas
Pharma Mar: Randomised, controlled, open-label, phase IIb/III study of Lurbinectedin in combination with Doxorubicin vs. Doxorubicin alone as a first-line treatment in patients with metastatic leiomyosarcoma.
rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
IDRX-42-301: StrateGIST: A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy.
** Sometimes there may be other trials open - it is always worth asking your doctor. **
